PL3697418T3 - Polepszone preparaty bromokryptyny - Google Patents
Polepszone preparaty bromokryptynyInfo
- Publication number
- PL3697418T3 PL3697418T3 PL18868516.8T PL18868516T PL3697418T3 PL 3697418 T3 PL3697418 T3 PL 3697418T3 PL 18868516 T PL18868516 T PL 18868516T PL 3697418 T3 PL3697418 T3 PL 3697418T3
- Authority
- PL
- Poland
- Prior art keywords
- improved
- bromocriptine formulations
- formulations
- improved bromocriptine
- bromocriptine
- Prior art date
Links
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 title 1
- 229960002802 bromocriptine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573839P | 2017-10-18 | 2017-10-18 | |
| PCT/US2018/056554 WO2019079623A1 (en) | 2017-10-18 | 2018-10-18 | ENHANCED BROMOCRIPTINE FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3697418T3 true PL3697418T3 (pl) | 2025-02-03 |
Family
ID=66174253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18868516.8T PL3697418T3 (pl) | 2017-10-18 | 2018-10-18 | Polepszone preparaty bromokryptyny |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11510921B2 (pl) |
| EP (2) | EP3697418B1 (pl) |
| JP (3) | JP7231255B2 (pl) |
| CN (1) | CN111818921A (pl) |
| AU (2) | AU2018351131B2 (pl) |
| CA (1) | CA3079522A1 (pl) |
| DK (1) | DK3697418T3 (pl) |
| ES (1) | ES2991048T3 (pl) |
| HR (1) | HRP20241365T1 (pl) |
| PL (1) | PL3697418T3 (pl) |
| WO (1) | WO2019079623A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| CN120713906A (zh) | 2016-04-20 | 2025-09-30 | 维罗技术有限责任公司 | 用于治疗代谢失调的组合物和方法 |
| EP3697418B1 (en) * | 2017-10-18 | 2024-07-24 | VeroScience LLC | Improved bromocriptine formulations |
| WO2021061818A1 (en) | 2019-09-23 | 2021-04-01 | Veroscience Llc | Method for inducing tumor regression |
| US20230312885A1 (en) * | 2022-03-11 | 2023-10-05 | Celanese International Corporation | Cellulose Ester Polymer Product With Increased Melt Flow Rate |
| CN122206668A (zh) * | 2023-09-28 | 2026-06-12 | 上海翱路生物医药科技有限公司 | 化合物、组合物及其方法 |
| CN121695098A (zh) * | 2026-02-11 | 2026-03-20 | 上海瀚合瑞医药科技有限公司 | 一种甲磺酸溴隐亭肠溶片及其制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US941005A (en) | 1906-03-24 | 1909-11-23 | Brandt Company | Designating, recording, and registering mechanism. |
| CH507249A (de) | 1968-05-31 | 1971-05-15 | Sandoz Ag | Verfahren zur Herstellung von 2-Brom-a-ergokryptin |
| GB8426922D0 (en) | 1984-10-24 | 1984-11-28 | Sandoz Ltd | Galenic formulation |
| US4749709A (en) | 1986-03-07 | 1988-06-07 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
| US4783469A (en) | 1986-03-07 | 1988-11-08 | Meier Albert H | Method of inhibiting body fat stores |
| US4659715A (en) | 1986-03-07 | 1987-04-21 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
| DE3722383A1 (de) | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
| US4962197A (en) | 1988-02-12 | 1990-10-09 | Rowland Institute For Science | Photo-inactivation of cancer cells |
| US6004972A (en) | 1988-05-10 | 1999-12-21 | The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of type II diabetes |
| US5700800A (en) | 1988-05-10 | 1997-12-23 | Ergo Science Incorporated | Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound |
| US5716933A (en) | 1988-05-10 | 1998-02-10 | Louisiana State University And Agricultural And Mechanical College | Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates |
| US5830895A (en) | 1988-05-10 | 1998-11-03 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods for the determination and adjustment of prolactin daily rhythms |
| US5468755A (en) | 1988-05-10 | 1995-11-21 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Therapeutic process for the treatment of the pathologies of Type II diabetes |
| US5668155A (en) | 1988-05-10 | 1997-09-16 | The General Hospital Corporation | Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders |
| US5344832A (en) | 1990-01-10 | 1994-09-06 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| US5585347A (en) | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| US5744477A (en) | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
| US5006526A (en) | 1988-10-17 | 1991-04-09 | Louisiana State University | Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis |
| JPH02121919A (ja) * | 1988-10-28 | 1990-05-09 | Grelan Pharmaceut Co Ltd | 柔軟性を有する錠剤 |
| IT1235053B (it) | 1989-04-07 | 1992-06-17 | Poli Ind Chimica Spa | Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti. |
| CA2030174C (en) | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates |
| FR2680106B1 (fr) | 1991-08-09 | 1994-03-11 | Corbiere Gerome | Procede de realisation de formes pharmaceutiques stables d'un derive d'ergoline et les compositions pharmaceutiques ainsi obtenues. |
| US5186420A (en) | 1991-11-08 | 1993-02-16 | The United States Of America As Represented By The Secretary Of The Navy | Articulated fin/wing control system |
| US5696128A (en) | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| DE4322826A1 (de) * | 1993-07-08 | 1995-01-12 | Galenik Labor Freiburg Gmbh | Pharmazeutisches Präparat |
| IL112106A0 (en) | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
| US5565454A (en) | 1995-05-31 | 1996-10-15 | Ergo Science, Incorporated | Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions |
| US5792748A (en) | 1995-06-07 | 1998-08-11 | The General Hospital Corporation | Method for inhibiting neoplastic disease in mammals |
| US5626860A (en) | 1995-06-07 | 1997-05-06 | The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College | Method for regulating metabolism with dopamine beta hydroxylase inhibitors |
| US5714519A (en) | 1995-06-07 | 1998-02-03 | Ergo Science Incorporated | Method for regulating glucose metabolism |
| WO1997026885A1 (en) | 1996-01-23 | 1997-07-31 | The General Hospital Corporation Doing Business As Massachusetts General Hospital | Benzophenothiazine and benzoporphyrin dye combination photodynamic therapy of tumors |
| DK0910365T3 (da) | 1996-05-01 | 2003-10-20 | Harvard College | Væksthæmning og udslettelse af faste tumorer ved at anvende en prolactinmodulator og en fotosensibilisator |
| US20010016582A1 (en) | 1997-04-28 | 2001-08-23 | Anthony H. Cincotta | Method and composition for the treatment of lipid and glucose metabolism disorders |
| US5877183A (en) | 1996-06-06 | 1999-03-02 | Ergo Research Corporation | Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists |
| EP0834308A1 (en) | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
| WO2001051088A1 (en) | 2000-01-07 | 2001-07-19 | Anthony Cincotta | Composition for reducing plasma triglycerides, platelet aggregation, and oxidative capacity |
| WO2002083141A1 (en) | 2001-04-17 | 2002-10-24 | Pharmacia & Upjohn Company | Treatment of fibromyalgia and chronic fatigue syndrome |
| AU2002348477A1 (en) | 2001-05-01 | 2002-12-23 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| US20040220190A1 (en) | 2002-07-29 | 2004-11-04 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20050054652A1 (en) | 2002-07-29 | 2005-03-10 | Cincotta Anthony H. | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US20040077679A1 (en) | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| US20080200453A1 (en) | 2002-07-29 | 2008-08-21 | Cincotta Anthony H | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US20040081678A1 (en) | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| WO2005072292A2 (en) | 2004-01-24 | 2005-08-11 | Hugh Mctavish | Methods for enhancing radiation therapy |
| US8137994B2 (en) | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US8137993B2 (en) | 2004-03-25 | 2012-03-20 | Veroscience Llc | Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof |
| US20050215558A1 (en) | 2004-03-25 | 2005-09-29 | Cincotta Anthony H | Methods of identifying responders to dopamine agonist therapy |
| US7528108B2 (en) * | 2005-04-26 | 2009-05-05 | Ambryx Biotechnology, Inc. | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments |
| US20210401824A1 (en) | 2007-06-21 | 2021-12-30 | Veroscience Llc | Parenteral Formulations of Dopamine Agonists |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| EP3524248A1 (en) | 2007-06-21 | 2019-08-14 | VeroScience LLC | Method of treating metabolic disorders and depression with dopamine receptor agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US8877708B2 (en) | 2009-06-05 | 2014-11-04 | Veroscience, Llc | Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| RU2012157977A (ru) | 2010-06-08 | 2014-07-20 | ВЕРОСАЙЕНС ЭлЭлСи | Терапевтическое лечение метаболического синдрома, диабета 2 типа, ожирения или предиабета |
| CN102283844B (zh) * | 2010-06-21 | 2014-06-25 | 山东新时代药业有限公司 | 含有克拉维酸的药物组合物及其用途 |
| JP2014514367A (ja) | 2010-11-15 | 2014-06-19 | サン ケミカル コーポレイション | 印刷用インクの凝固特性および耐摩擦性を改善するための組成物および方法 |
| CN103282035A (zh) | 2010-11-23 | 2013-09-04 | Vero科学有限责任公司 | 治疗代谢综合征、2型糖尿病、肥胖或前驱糖尿病的治疗剂 |
| CN102727894B (zh) | 2011-04-01 | 2015-10-07 | 鲁南制药集团股份有限公司 | 一种治疗糖尿病及其并发症的药物组合物及其应用 |
| TWI442945B (zh) | 2011-05-18 | 2014-07-01 | Univ Nat Taiwan | 雙效微脂體用於治療的方法 |
| US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
| WO2014004951A1 (en) | 2012-06-28 | 2014-01-03 | Kean University | Novel fatty acid-salicylate conjugates with enhanced therapeutic properties |
| EP3311842A1 (en) | 2013-06-13 | 2018-04-25 | VeroScience LLC | Compositions and methods for treating metabolic disorders |
| JP6370630B2 (ja) | 2014-07-31 | 2018-08-08 | 株式会社ニューフレアテクノロジー | 気相成長装置および気相成長方法 |
| CN120713906A (zh) | 2016-04-20 | 2025-09-30 | 维罗技术有限责任公司 | 用于治疗代谢失调的组合物和方法 |
| US20170340271A1 (en) | 2016-05-26 | 2017-11-30 | Veroscience Llc | Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions |
| EP3697418B1 (en) | 2017-10-18 | 2024-07-24 | VeroScience LLC | Improved bromocriptine formulations |
| WO2021061818A1 (en) | 2019-09-23 | 2021-04-01 | Veroscience Llc | Method for inducing tumor regression |
-
2018
- 2018-10-18 EP EP18868516.8A patent/EP3697418B1/en active Active
- 2018-10-18 US US16/623,183 patent/US11510921B2/en active Active
- 2018-10-18 PL PL18868516.8T patent/PL3697418T3/pl unknown
- 2018-10-18 JP JP2020522290A patent/JP7231255B2/ja active Active
- 2018-10-18 CN CN201880081067.9A patent/CN111818921A/zh active Pending
- 2018-10-18 DK DK18868516.8T patent/DK3697418T3/da active
- 2018-10-18 CA CA3079522A patent/CA3079522A1/en active Pending
- 2018-10-18 ES ES18868516T patent/ES2991048T3/es active Active
- 2018-10-18 EP EP23176381.4A patent/EP4233913A3/en active Pending
- 2018-10-18 HR HRP20241365TT patent/HRP20241365T1/hr unknown
- 2018-10-18 AU AU2018351131A patent/AU2018351131B2/en active Active
- 2018-10-18 WO PCT/US2018/056554 patent/WO2019079623A1/en not_active Ceased
-
2022
- 2022-05-03 US US17/735,217 patent/US11883399B2/en active Active
-
2023
- 2023-02-09 JP JP2023018110A patent/JP7586523B2/ja active Active
- 2023-06-14 US US18/209,699 patent/US12274698B2/en active Active
-
2024
- 2024-08-28 AU AU2024216408A patent/AU2024216408B2/en active Active
- 2024-10-30 JP JP2024190314A patent/JP2025011338A/ja active Pending
-
2025
- 2025-03-17 US US19/081,823 patent/US20250275961A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3697418A4 (en) | 2021-07-14 |
| EP3697418B1 (en) | 2024-07-24 |
| EP3697418A1 (en) | 2020-08-26 |
| EP4233913A2 (en) | 2023-08-30 |
| JP2023055940A (ja) | 2023-04-18 |
| US20230321090A1 (en) | 2023-10-12 |
| AU2018351131A1 (en) | 2020-05-07 |
| JP7231255B2 (ja) | 2023-03-01 |
| EP4233913A3 (en) | 2023-10-18 |
| JP7586523B2 (ja) | 2024-11-19 |
| US20250275961A1 (en) | 2025-09-04 |
| US12274698B2 (en) | 2025-04-15 |
| WO2019079623A1 (en) | 2019-04-25 |
| US11883399B2 (en) | 2024-01-30 |
| US20220265648A1 (en) | 2022-08-25 |
| JP2021500357A (ja) | 2021-01-07 |
| CN111818921A (zh) | 2020-10-23 |
| AU2024216408A1 (en) | 2024-09-19 |
| HRP20241365T1 (hr) | 2024-12-20 |
| AU2024216408B2 (en) | 2026-04-30 |
| CA3079522A1 (en) | 2019-04-25 |
| JP2025011338A (ja) | 2025-01-23 |
| AU2018351131B2 (en) | 2024-05-30 |
| DK3697418T3 (da) | 2024-10-07 |
| US11510921B2 (en) | 2022-11-29 |
| ES2991048T3 (es) | 2024-12-02 |
| US20210177839A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL273282A (en) | Niraprib formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL265609A (en) | New formulations | |
| GB201703455D0 (en) | Composition | |
| GB201607918D0 (en) | Novel formulations | |
| GB201707120D0 (en) | Composition | |
| GB201707189D0 (en) | Novel formulations | |
| EP3697418A4 (en) | IMPROVED BROMOCRIPTIN FORMULATIONS | |
| GB201707188D0 (en) | Novel formulations | |
| GB201700504D0 (en) | Composition | |
| IL272526A (en) | Enhanced endoinulinase proteins | |
| PL3727015T3 (pl) | Strukturanty na bazie białka roślinnego | |
| GB201707187D0 (en) | Novel formulations | |
| GB201712151D0 (en) | Composition | |
| GB201711446D0 (en) | Composition | |
| GB201709905D0 (en) | Composition | |
| GB201707920D0 (en) | Composition | |
| GB201717224D0 (en) | Composition | |
| GB201715135D0 (en) | Composition | |
| GB201707210D0 (en) | Improved hitchlock | |
| GB201703457D0 (en) | Composition | |
| GB201700095D0 (en) | Composition | |
| IL268195A (en) | Solid fosmetpantothenate formulations |